ERN1: A Protein Involved in NSC Proliferation and Differentiation

Target Name: ERN1

NCBI ID: G2081

ERN1

ERN1: A Protein Involved in NSC Proliferation and Differentiation

ERN1 (IRE1), also known as Calbindin, is a protein that is expressed in various tissues throughout the body, including the lungs, heart, kidneys, and pancreas. It is a member of the calbindin family of proteins, which are involved in the regulation of cell signaling and cytoskeletal organization.

One of the key functions of ERN1 is its role in the regulation of neural stem cell (NSC) proliferation and differentiation. NSC are a type of cell that have the ability to give rise to many different cell types in the nervous system, and they play a crucial role in the development and maintenance of neural tissue.

Research has shown that ERN1 plays a critical role in the regulation of NSC proliferation and differentiation by promoting the expression of genes that are involved in cell growth and survival. This is done through the interaction of ERN1 with several other proteins, including the transcription factor p53.

In addition to its role in the regulation of NSC proliferation and differentiation, ERN1 has also been shown to play a key role in the regulation of inflammation. NSC that have been modified to express higher levels of ERN1 have been shown to be more susceptible to inflammation than NSC that have lower levels of ERN1. This suggests that ERN1 may be a potential drug target for the treatment of inflammatory diseases.

ERN1 has also been shown to play a role in the regulation of cell migration and the assembly of tissues. This is done through its interaction with the protein vimentin, which is involved in the formation of tight junctions between cells.

In conclusion, ERN1 is a protein that has been shown to play a critical role in the regulation of NSC proliferation and differentiation, as well as inflammation and cell migration. As a result, ERN1 may be a potential drug target for the treatment of a variety of diseases. Further research is needed to fully understand the role of ERN1 in these processes and to develop effective treatments.

Protein Name: Endoplasmic Reticulum To Nucleus Signaling 1

Functions: Serine/threonine-protein kinase and endoribonuclease that acts as a key sensor for the endoplasmic reticulum unfolded protein response (UPR) (PubMed:11175748, PubMed:11779464, PubMed:12637535, PubMed:21317875, PubMed:28128204, PubMed:9637683, PubMed:30118681). In unstressed cells, the endoplasmic reticulum luminal domain is maintained in its inactive monomeric state by binding to the endoplasmic reticulum chaperone HSPA5/BiP (PubMed:21317875). Accumulation of misfolded proteins in the endoplasmic reticulum causes release of HSPA5/BiP, allowing the luminal domain to homodimerize, promoting autophosphorylation of the kinase domain and subsequent activation of the endoribonuclease activity (PubMed:21317875). The endoribonuclease activity is specific for XBP1 mRNA and excises 26 nucleotides from XBP1 mRNA (PubMed:11779464, PubMed:24508390, PubMed:21317875). The resulting spliced transcript of XBP1 encodes a transcriptional activator protein that up-regulates expression of UPR target genes (PubMed:11779464, PubMed:24508390, PubMed:21317875). Acts as an upstream signal for ER stress-induced GORASP2-mediated unconventional (ER/Golgi-independent) trafficking of CFTR to cell membrane by modulating the expression and localization of SEC16A (PubMed:21884936, PubMed:28067262)

The "ERN1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ERN1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets